<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856869</url>
  </required_header>
  <id_info>
    <org_study_id>NRL972-02/2003(ACPS)</org_study_id>
    <nct_id>NCT00856869</nct_id>
  </id_info>
  <brief_title>Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers</brief_title>
  <official_title>A Study in Healthy Volunteers and Patients With Liver Cirrhosis and Non-Alcoholic Steatohepatitis (NASH) to Assess the Effects of Age, Gender, Chronic Liver Disease, and Prandial Effects on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) an an in-Vivo Marker of Liver Function in Man.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was conducted to describe and compare the plasma pharmacokinetics of NRL972
      administered after a standard meal and while fasted in patients with hepatic cirrhosis
      (Child-Turcotte-Pugh [CTP] class A-C), NASH, young and elderly healthy males, and young and
      elderly healthy females, to assess the effects of liver dysfunction, gender, age and prandial
      intestinal hyperaemia on the clearance of NRL972. In addition, the study was to provide
      information on the safety and tolerability of repeated intravenous doses of NRL972 in these
      populations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of NRL972 after a standard meal and while fasted in healthy volunteers, patients with NASH and patients with hepatic cirrhosis.</measure>
    <time_frame>Up to 4 hours post administration of NRL972</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events and changes in physical findings from baseline</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of vital signs: blood pressure, pulse rate</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on electrocardiogram</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in haematology, clinical chemistry, urinalysis</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Hepatic Cirrhosis</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>1 YM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy young males</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 EM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly males</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 YF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy young females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 EF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 NASH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with presumed NASH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 CTP-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hepatic cirrhosis CTP-class A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 CTP-BC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hepatic cirrhosis CTP-class B and C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>1 YM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>2 EM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>3 YF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>4 EF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>5 NASH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>6 CTP-A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>7 CTP-BC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General - all subjects

          1. Males or females (females of non-childbearing potential or of childbearing potential
             while taking medically appropriate contraception)

          2. Caucasian

          3. BMI: between 19 and 34 kg.m-2

          4. BW: between 45 and 110 kg

          5. willing and able to provide informed consent Healthy volunteers (group N)

          6. Age: 18 - 40 years (inclusive) e.g. &gt; 60 years

          7. Assessed as healthy based on the pre study examination Hepatic cirrhosis

          8. Age: 18 - 75 years

          9. stable compensated liver cirrhosis (cryptogenic, posthepatic, alcoholic) with
             histo-logical or macroscopic (e.g. laparascopy, biopsy, ultrasound sonography or other
             adequate imaging techniques) confirmation Nonalcoholic steatohepatitis (NASH)

         10. Age: 18 - 75 years

         11. Diagnosis of NASH confirmed by liver biopsy

        Exclusion Criteria:

        General - all subjects

          1. Previous participation in the trial

          2. Participant in any other trial during the last 90 days

          3. Donation of blood during the last 60 days or a history of blood loss exceeding 450 mL
             within the last 3 months

          4. History of any clinically relevant allergy

          5. Uncontrolled diabetes mellitus or any further intolerability of the Galactose test

          6. Presence of acute or chronic infection

          7. Resting systolic blood pressure &gt; 160 or &lt; 90 mmHg, diastolic blood pressure &gt; 95 or &lt;
             50 mmHg

          8. Clinically relevant ECG-abnormalities, prolonged QTc with &gt; 450 msec in males and &gt;
             460 msec in females in particular

          9. Clinically relevant ECG-abnormalities that constitute a contraindication for the
             Lido-cain-MEG'-X-test

         10. Positive HIV test

         11. Positive alcohol or urine drug test on recruitment

         12. Daily use of &gt; 30 gr alcohol

         13. Smoking more than 15 cigarettes/day or equivalent of other tobacco products

         14. Use of prohibited medication

         15. Suspicion or evidence that the subject is not trustworthy and reliable

         16. Suspicion or evidence that the subject is not able to make a free consent or to
             under-stand the information in this regard

             General - all females

         17. Positive pregnancy test

         18. Lactating

         19. Not using appropriate contraception in premenopausal women All healthy subjects

         20. Presence or history of any relevant comorbidity (list of past and present diseases
             will be reviewed by an expert panel)

         21. Presence of any relevant abnormality in the laboratory safety tests, especially low
             haemoglobin, increased liver enzymes, reduced serum creatinine (laboratory test
             abnormalities will be reviewed by an expert panel)

         22. Positive serology for HBsAg, anti HBc and anti HCV

         23. History of alcohol and/or drug abuse.

             Patients with hepatic disease

         24. Biliary liver cirrhosis

         25. Liver impairment due to space-occupying processes (e.g. carcinoma)

         26. State after liver transplantation or patient scheduled for liver transplantation

         27. Fluctuating or rapidly deteriorating hepatic function

         28. Significant bleeding diathesis

         29. Oesophageal bleeding within the last 8 weeks before study entry

         30. Ascites &gt; 6 L on abdominal US

         31. Number Connection test: time to connect 25 consecutive numbers &gt; 30 sec

         32. Presence or history of any relevant comorbidity other than hepatic disease (list of
             past and present diseases will be reviewed by an expert panel)

         33. Clinically relevant abnormal laboratory values other than those associated or
             sufficiently explained by the existing liver disease (laboratory test abnormalities
             will be reviewed by an expert panel)

         34. History of drug or alcohol abuse within 2 months prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zahariy Krastev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Ivan Rilski's University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans-JÃ¼rgen Gruss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMHAPT St. Ivan Rilski's University Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>March 5, 2009</last_update_submitted>
  <last_update_submitted_qc>March 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vice President Clinical Development</name_title>
    <organization>Norgine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

